| scholarly article | Q13442814 |
| P50 | author | Brett M. Kissela | Q39033790 |
| P2093 | author name string | D Woo | |
| J P Broderick | |||
| K Alwell | |||
| P Sekar | |||
| C J Moomaw | |||
| D Kleindorfer | |||
| M Haverbusch | |||
| M L Flaherty | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | anticoagulation | Q63279445 |
| anticoagulant | Q215118 | ||
| P304 | page(s) | 116-121 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | Neurology | Q1161692 |
| P1476 | title | The increasing incidence of anticoagulant-associated intracerebral hemorrhage | |
| P478 | volume | 68 |
| Q37417509 | A systematic review of Cochrane anticoagulation reviews. |
| Q38228428 | Acute stroke in patients on new direct oral anticoagulants: how to manage, how to treat? |
| Q36944012 | Advances in hemorrhagic stroke therapy: conventional and novel approaches |
| Q37793839 | Advances in the management of intracerebral hemorrhage |
| Q30825729 | Advances in understanding spontaneous intracerebral hemorrhage: insights from neuroimaging |
| Q30975560 | Anticoagulation for Atrial Fibrillation in Patients with Cerebral Microbleeds |
| Q88000130 | Anticoagulation for atrial fibrillation after intracranial hemorrhage: A systematic review |
| Q36956325 | Anticoagulation in atrial fibrillation: selected controversies including optimal anticoagulation intensity, treatment of intracerebral hemorrhage |
| Q43622937 | Anticoagulation in the setting of intracerebral hemorrhage: controversies in resuming therapy |
| Q45769042 | Anticoagulation management of myocardial infarction after deep brain stimulation: a comparison of two cases |
| Q38013666 | Anticoagulation-related intracranial hemorrhages |
| Q34850774 | Antiplatelet/anticoagulant agents and chronic subdural hematoma in the elderly |
| Q45040270 | Antithrombotic Medication Use and Misuse Among Patients with Intracranial Hemorrhage: A 16-Year, Lebanese, Single-Center Experience. |
| Q92358437 | Antithrombotic drugs do not increase intraoperative blood loss in emergency gastrointestinal surgery: a single-institution propensity score analysis |
| Q92955488 | Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline |
| Q37496293 | Atrial Fibrillation - A Common Ground for Neurology and Cardiology |
| Q49428555 | Atrial Fibrillation for the Neurologist: Preventing both Ischemic and Hemorrhagic Strokes |
| Q50963379 | Audit on the usage of plasma derived/recombinant coagulation factor concentrates at a German university hospital. |
| Q47185519 | Before-After Study of an Electronic Order Set for Reversal of Vitamin K Antagonist-Associated Intracerebral Hemorrhage. |
| Q61451055 | Bleeding Complications in Warfarin-Treated Patients Admitted to the Emergency Department |
| Q33841770 | Bleeding complications associated with warfarin treatment in ischemic stroke patients with atrial fibrillation: a population-based cohort study |
| Q37868373 | Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis |
| Q39126853 | Cerebral Amyloid Angiopathy in Stroke Medicine. |
| Q37790450 | Cerebral amyloid angiopathy in East and West. |
| Q37662448 | Cerebral microbleeds and macrobleeds: should they influence our recommendations for antithrombotic therapies? |
| Q30570918 | Cerebral microbleeds on magnetic resonance imaging and anticoagulant-associated intracerebral hemorrhage risk |
| Q38109534 | Cerebral microbleeds: a guide to detection and clinical relevance in different disease settings |
| Q37082606 | Cerebral microbleeds: a new dilemma in stroke medicine |
| Q40212101 | Change in incidence and aetiology of intracerebral haemorrhage in Oxfordshire, UK, between 1981 and 2006: a population-based study |
| Q93092340 | Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial |
| Q98194136 | Clinical Impact of Hematoma Expansion in Left Ventricular Assist Device Patients |
| Q37159030 | Clinical epidemiology of atrial fibrillation and related cerebrovascular events in the United States |
| Q45670077 | Coagulopathy disproportionately predisposes to lobar intracerebral hemorrhage |
| Q52148994 | Combined clopidogrel-aspirin treatment for high risk TIA or minor stroke does not increase cerebral microbleeds. |
| Q37528205 | Comparison of CHADS2 and CHA2DS2-VASC anticoagulation recommendations: evaluation in a cohort of atrial fibrillation ablation patients |
| Q45139213 | Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials |
| Q33791638 | Costs of major intracranial, gastrointestinal and other bleeding events in patients with atrial fibrillation - a nationwide cohort study |
| Q90632684 | Description of a Novel Phosphodiesterase (PDE)-3 Inhibitor Protecting Mice From Ischemic Stroke Independent From Platelet Function |
| Q38170028 | Do current animal models of intracerebral hemorrhage mirror the human pathology? |
| Q46979280 | Effectiveness of Factor IX complex concentrate in reversing warfarin associated coagulopathy for intracerebral hemorrhage |
| Q45854165 | Effects of celecoxib on hematoma and edema volumes in primary intracerebral hemorrhage: a multicenter randomized controlled trial |
| Q57823155 | Elevated International Normalized Ratio Is Associated With Ruptured Aneurysms |
| Q37166752 | Eligibility for the surgical trial in intracerebral hemorrhage II study in a population-based cohort |
| Q37314490 | Emergency department ultrasound diagnosis of spontaneous iliopsoas haemorrhage in a patient on warfarin |
| Q46827302 | Emergency reversal of clopidogrel in the setting of spontaneous intracerebral hemorrhage |
| Q36266774 | Epidemiology of Intracranial Haemorrhages Associated with Vitamin K Antagonist Oral Anticoagulants in Spain: TAC Registry |
| Q30238502 | Epidemiology, Risk Factors, and Clinical Features of Intracerebral Hemorrhage: An Update |
| Q36978858 | Evidence-based medicine and the Cochrane Collaboration on trial. |
| Q26862513 | Evolving management of symptomatic chronic subdural hematoma: experience of a single institution and review of the literature |
| Q37017480 | Experimental model of warfarin-associated intracerebral hemorrhage |
| Q47213606 | Factors associated with availability of anticoagulation reversal agents in rural and community emergency departments. |
| Q37580876 | Fixed Versus Variable Dosing of Prothrombin Complex Concentrate in Vitamin K Antagonist-Related Intracranial Hemorrhage: A Retrospective Analysis |
| Q37066273 | Genetic elimination of prothrombin in adult mice is not compatible with survival and results in spontaneous hemorrhagic events in both heart and brain. |
| Q38682353 | Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine. |
| Q35711431 | Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association |
| Q22306356 | Heart Disease and Stroke Statistics--2013 Update: A Report From the American Heart Association |
| Q29547236 | Heart disease and stroke statistics--2011 update: a report from the American Heart Association |
| Q29547909 | Heart disease and stroke statistics--2012 update: a report from the American Heart Association |
| Q29547691 | Heart disease and stroke statistics--2014 update: a report from the American Heart Association |
| Q38734794 | Hematoma Expansion following Intracerebral Hemorrhage: Mechanisms Targeting the Coagulation Cascade and Platelet Activation. |
| Q39209982 | Hemostasis in Intracranial Hemorrhage |
| Q36072031 | International epidemiology of intracerebral hemorrhage |
| Q33442365 | Intracerebral haemorrhage |
| Q39473342 | Intracerebral haemorrhage profiles are changing: results from the Dijon population-based study |
| Q52147059 | Intracerebral haemorrhage, atrial fibrillation, and anticoagulation. |
| Q43574054 | Intracerebral hemorrhage during anticoagulation with vitamin K antagonists: a consecutive observational study |
| Q38113483 | Intracerebral hemorrhage in patients receiving oral anticoagulation therapy |
| Q33961784 | Intracerebral hemorrhage mortality is not changing despite declining incidence |
| Q35988434 | Intracerebral hemorrhage: toward physiological imaging of hemorrhage risk in acute and chronic bleeding |
| Q34381680 | Location and characteristics of warfarin associated intracranial hemorrhage. |
| Q33405392 | Long-term safety and efficacy of a pasteurized nanofiltrated prothrombin complex concentrate (Beriplex P/N): a pharmacovigilance study |
| Q33579357 | Low cholesterol level associated with severity and outcome of spontaneous intracerebral hemorrhage: Results from Taiwan Stroke Registry |
| Q33750215 | Management of anticoagulant-related intracranial hemorrhage: an evidence-based review. |
| Q44557173 | Management of asymptomatic carotid artery stenosis. |
| Q81593148 | Management of intracerebral hemorrhage |
| Q38101165 | Management of intracerebral hemorrhage in the presence of anticoagulant therapy |
| Q37867296 | Management of spontaneous nontraumatic intracranial hemorrhage |
| Q37083648 | Management of warfarin-related intracerebral hemorrhage |
| Q36973381 | Managing anticoagulant related coagulopathy |
| Q26991728 | Managing anticoagulation for atrial fibrillation: current issues and future strategies |
| Q30410308 | Meta-analysis of genome-wide association studies identifies 1q22 as a susceptibility locus for intracerebral hemorrhage |
| Q38389058 | Minimizing the risk of hemorrhagic stroke during anticoagulant therapy for atrial fibrillation. |
| Q34677974 | Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation |
| Q37598901 | New avenues for treatment of intracranial hemorrhage |
| Q38087191 | Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation |
| Q37900185 | Oral anticoagulant-associated intracerebral hemorrhage |
| Q37274433 | Perioperative management of coagulation in nontraumatic intracerebral hemorrhage |
| Q45082550 | Pharmacologically-induced neurocatastrophes |
| Q36185368 | Postoperative anticoagulation in patients with mechanical heart valves following surgical treatment of subdural hematomas |
| Q36258652 | Prediction of individual combined benefit and harm for patients with atrial fibrillation considering warfarin therapy: a study protocol |
| Q92502245 | Predictors of cerebrovascular event reoccurrence in patients with depression: a retrospective cohort study |
| Q34459723 | Progressing haemorrhagic stroke: categories, causes, mechanisms and managements |
| Q58803005 | Quality of Chronic Anticoagulation Control in Patients with Intracranial Haemorrhage due to Vitamin K Antagonists |
| Q47274437 | Recurrent Hemorrhagic Conversion of Ischemic Stroke in a Patient with Mechanical Heart Valve: A Case Report and Literature Review |
| Q48152726 | Replacing warfarin with a novel oral anticoagulant: Risk of recurrent bleeding and stroke in patients with warfarin ineligible or failure in patients with atrial fibrillation (The ROAR study). |
| Q34555332 | Restarting Anticoagulant Therapy After Intracranial Hemorrhage: A Systematic Review and Meta-Analysis |
| Q47891553 | Resumption of Anticoagulation After Intracranial Hemorrhage |
| Q36928194 | Reversal of Vitamin K Antagonist (VKA) effect in patients with severe bleeding: a French multicenter observational study (Optiplex) assessing the use of Prothrombin Complex Concentrate (PCC) in current clinical practice |
| Q38269290 | Reversal of anticoagulant effects in patients with intracerebral hemorrhage. |
| Q39037122 | Review And Insights Into The Bleeding Mechanism Incited By Antithrombotic Therapy: Mechanistic Nuances Of Dual Pro-Hemorrhagic Substrate Incorporating Drug-Induced Microvascular Leakage |
| Q35768553 | Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents |
| Q37624211 | Risk Factors for Bleeding in Hospitalized at Risk Patients With an INR of 5 or More Treated With Vitamin K Antagonists |
| Q35018742 | Risk of thromboembolism following acute intracerebral hemorrhage |
| Q99616760 | Sensitivity and specificity of blood-fluid levels for oral anticoagulant-associated intracerebral haemorrhage |
| Q36933765 | Should anticoagulation be resumed after intracerebral hemorrhage? |
| Q33844772 | Spontaneous intraventricular hemorrhage associated with prolonged diosmin therapy |
| Q37469069 | Stroke And Bleeding Risk Assessment: Where Are We Now? |
| Q38244278 | Stroke and bleeding risk in atrial fibrillation: navigating the alphabet soup of risk-score acronyms (CHADS2 , CHA2 DS2 -VASc, R2 CHADS2 , HAS-BLED, ATRIA, and more). |
| Q37280327 | Surgical management and case-fatality rates of intracerebral hemorrhage in 1988 and 2005 |
| Q37293606 | Temporal Trends in Incidence and Case Fatality of Intracerebral Hemorrhage: The Tromsø Study 1995-2012. |
| Q51536148 | Temporal Trends in Risk Factors and Outcome of Intracerebral Hemorrhage Over 18 Years at a Tertiary Care Hospital in Karachi, Pakistan |
| Q55713145 | Testing for CYP2C9 Before Anticoagulant Therapy. |
| Q40668067 | The Clinical Relevance of Microbleeds in Stroke study (CROMIS-2): rationale, design, and methods |
| Q36044903 | The H-ATOMIC Criteria for the Etiologic Classification of Patients with Intracerebral Hemorrhage. |
| Q80350629 | The bad news: stroke incidence is stable |
| Q37172710 | The challenge of designing a treatment trial for warfarin-associated intracerebral hemorrhage |
| Q28067962 | The critical care management of spontaneous intracranial hemorrhage: a contemporary review |
| Q46549547 | The epidemiology of intracerebral hemorrhage in the United States from 1979 to 2008. |
| Q37211999 | The glucagon-like peptide-1 receptor agonist exendin-4 ameliorates warfarin-associated hemorrhagic transformation after cerebral ischemia |
| Q37873969 | The practical management of intracerebral hemorrhage associated with oral anticoagulant therapy. |
| Q37013014 | Therapeutic management of acute intracerebral haemorrhage |
| Q35729599 | Therapeutic strategies in acute intracerebral hemorrhage |
| Q26830105 | Thrombolytic evacuation of intracerebral and intraventricular hemorrhage |
| Q40405381 | Treatment of acute intracerebral hemorrhage |
| Q37788997 | Treatment of coagulopathy in intracranial hemorrhage |
| Q35648063 | Treatment targets in intracerebral hemorrhage |
| Q37052828 | Update in intracerebral hemorrhage |
| Q48507011 | Update on the Treatment of Spontaneous Intraparenchymal Hemorrhage: Medical and Interventional Management |
| Q37107710 | Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls |
| Q39659827 | Utilization of antithrombotic therapy for stroke prevention in atrial fibrillation: a cross-sectional baseline analysis in general practice |
| Q38153233 | Validation of clinical prediction scores in patients with primary intracerebral hemorrhage. |
| Q42024671 | Vascular Dysfunction in Brain Hemorrhage: Translational Pathways to Developing New Treatments from Old Targets |
| Q36645135 | Volume and functional outcome of intracerebral hemorrhage according to oral anticoagulant type |
| Q83051107 | WITHDRAWN: Neurochirurgie d'urgence et AVK: retarder la chirurgie n'est pas nécessaire |
| Q37063465 | Warfarin reversal in anticoagulant-associated intracerebral hemorrhage |
| Q37454438 | Warfarin sensitivity genotyping: a review of the literature and summary of patient experience |
| Q44178621 | Warfarin therapy and incidence of cerebrovascular complications in left-sided native valve endocarditis. |
| Q41871107 | Warfarin use leads to larger intracerebral hematomas |
| Q28219363 | Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial |
| Q43122170 | Warfarin-induced intracerebral hemorrhage associated with microbleeds |
Search more.